The Filing Desk

Foghorn Therapeutics

FHTX · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

FHTX · Last close · November 19, 2026
$1.78
Value Foghorn Therapeutics yourself

Foghorn Therapeutics' revenue rose 36.8% to $31 million in fiscal 2025. Its operating margin was −279.5%, up from −454.3% a year earlier. Free cash flow was −$86 million. The diluted share count rose 14.7%.

Foghorn Therapeutics Inc. Latest fiscal year ended December 31, 2025 10-K filed March 11, 2026 · 0001628280-26-016814 Updated
Revenue
$31M
36.8%
Operating margin
−279.5%
174.8 pts
Net income
−$74M
 
Free cash flow
−$86M
 
Return on equity
—
 
Market cap
$129M
Nov 19 close
P/E
25.4x
On $0.07 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Foghorn Therapeutics does

Foghorn Therapeutics is a clinical stage biotechnology company, which means it has no approved products and is still testing drugs in people. It is developing medicines that work by correcting abnormal gene expression, the turning on and off of genes. It targets the chromatin regulatory system, a set of cell machinery that controls this process and that the company says is involved in about half of all cancers.

Its proprietary Gene Traffic Control platform is used to find and test targets in that system. The company says it has more than seven programs, with one drug candidate in Phase 1 testing. Targets include SMARCA2, CBP, EP300 and ARID1B. It works with small molecule drugs, including protein degraders, which mark a protein for destruction, and other kinds of inhibitors.

In December 2021 it signed a strategic collaboration with Eli Lilly and Company. Lilly started a Phase 1 trial of FHD-909, a SMARCA2 inhibitor, and dosed the first patient in October 2024. Foghorn has no product sales and depends on collaboration payments and outside funding.

Its biggest risks, as it describes them

  • It has a short operating history and no approved products, which makes it hard to judge.
  • It has lost money since it started and expects to keep losing money.
  • It will need substantial extra funding and may have to cut programs if it cannot raise it.
  • It has never earned revenue from product sales and may never be profitable.
  • Its ability to use its past tax losses to cut future taxes may be limited.
From Foghorn Therapeutics's annual report on Form 10-K, filed March 11, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Foghorn Therapeutics lost money in fiscal 2025: a net loss of $74 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments10152805681
Debt incl. finance leases00000
Net debt (negative means net cash)−101−52−80−56−81
Net debt to EBITDA—————
Debt to equity0.0x————
Interest coverage−52.9x—−30.4x——
Current ratio9.4x6.4x4.1x3.7x2.7x
Quick ratio9.4x6.4x4.1x3.7x2.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Foghorn Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Foghorn Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 80 of 82 of 8
Rule of 40−271.8%−482.1%−242.0%
Altman Z''−3.97−4.76−10.28
Accruals ratio5.7%4.8%4.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score1 of 80 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Foghorn Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Foghorn TherapeuticsFY2536.8%−279.5%−278.7%——2
VerastemFY25209.1%−550.3%————Compare
EyePointFY25−27.5%−776.0%−775.8%———Compare
ScilexFY25−46.5%−1,143.7%12.2%——3Compare
NanobiotixFY25—−33.2%−104.2%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—0119342331
Revenue growth——206.7%1,357.8%77.6%−33.8%36.8%
Gross profit———————
Research and development4458801061109486
Operating income−51−68−101−117−108−103−86
Net income−51−69−101−109−98−87−74
Diluted EPS (US$)−12.20−6.23−2.73−2.62−2.34−1.58−1.18
Diluted shares (millions)4113742425563
Cash flow
Cash from operations−46−31−50194−118−100−86
Capital expenditure11631110
Free cash flow−47−47−54192−119−101−86
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation23814161210
Balance sheet at fiscal year end
Cash and short-term investments159310152805681
Debt incl. finance leases15—00000
Total assets22256520405286284198
Total liabilities24109423405363330307
Shareholders' equity−88146970−77−46−108
Margins and ratios
Gross margin———————
Operating margin—−15,937.4%−7,637.1%−609.2%−315.9%−454.3%−279.5%
Net margin—−16,000.0%−7,681.6%−566.3%−288.2%−383.2%−240.3%
Free cash flow margin—−11,039.3%−4,060.9%1,000.6%−349.4%−448.2%−278.7%
Rule of 40 (growth + FCF margin)——−3,854.1%2,358.4%−271.8%−482.1%−242.0%
Return on capital———————
Return on equity—−236.5%−83.4%−224.5%———
Return on assets—−49.5%−26.1%−23.6%−28.5%−30.4%−30.8%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Foghorn Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Foghorn Therapeutics.